Ivosidenib as Post-HSCT Maintenance for AML
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona białaczka ostra szpikowa z mutacją IDH1
- •Wiek 18-75 lat
- •Planowane przeszczepienie komórek macierzystych krwi
- •Dobry stan ogólny pacjenta (ECOG ≤ 2)
- •Prawidłowe funkcje wątroby, nerek i serca
- •Wystarczająca liczba białych krwinek i płytek
- •Ujemny test ciąży (dla kobiet w wieku rozrodczym)
- •Zgoda na stosowanie antykoncepcji przez czas badania i 90 dni po
✗ Disqualifies
- •Poprzednie przeszczepienie komórek macierzystych krwi
- •Białaczka odporna na leczenie lub nawrócona
- •Historia innych nowotworów w ciągu ostatnich 5 lat
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- October 5, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (7)
Emory University Hospital
Atlanta, United States
Kansas University Medical Center
Kansas City, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Ohio State University Wexner Medical Center- James Cancer Hospital
Columbus, United States
Huntsman Cancer Institute, University of Utah
Salt Lake City, United States
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, United States
Trial contact
Amir T Fathi, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.